What is SecondWave Systems?
SecondWave Systems is a pioneering medical technology firm focused on the development of a novel, ultrasound-based wearable neuromodulation platform. By leveraging non-invasive acoustic energy, the company aims to provide patients and clinicians with a sophisticated, alternative treatment modality for debilitating and life-threatening diseases. Positioned at the intersection of digital health and advanced neuro-engineering, SecondWave Systems is addressing significant unmet clinical needs, aiming to improve patient outcomes while maintaining a focus on capital-efficient, scalable technology deployment.
How much funding has SecondWave Systems raised?
SecondWave Systems has raised a total of $17.4M across 3 funding rounds:
Angel/Seed
$7.4M
Other Financing Round
$3M
Series A
$7M
Angel/Seed (2021): $7.4M with participation from Department of Defense - Defense Advanced Research Projects Agency and U.S. Department of Defense
Other Financing Round (2024): $3M led by Advanced Research Projects Agency for Health and Department of Defense - Defense Advanced Research Projects Agency
Series A (2025): $7M supported by Sectoral Asset Management, Carlson School of Management - University of Minnesota, Scientific Health Development, and Treo Ventures
Key Investors in SecondWave Systems
Sectoral Asset Management
An investment advisor specializing in managing equities globally within the healthcare sector, offering a range of public and private equity strategies including biotech and emerging markets.
Scientific Health Development
A Dallas-based venture capital firm established in 2006 that specializes in investing in early-stage medtech companies targeting unmet clinical needs.
Treo Ventures
A capital fund founded in 2018 that focuses on medical device and digital health innovation targeting large, unmet healthcare needs.
What's next for SecondWave Systems?
With the successful closure of this major strategic investment, SecondWave Systems is well-positioned to accelerate its clinical validation and regulatory pathways. The infusion of capital will likely be directed toward scaling manufacturing capabilities and expanding the research team to support the transition from prototype to commercial-ready medical device. As the company moves deeper into its Series A phase, the focus will shift toward establishing long-term clinical efficacy data and forging strategic partnerships within the broader healthcare ecosystem to ensure the successful adoption of its neuromodulation platform. The involvement of specialized medtech investors suggests a clear path toward market entry and long-term value creation in the neuro-therapeutic space.
See full SecondWave Systems company page
